← Back to Screener
Phio Pharmaceuticals Corp. Common Stock (PHIO)
Price$1.27
Favorite Metrics
Price vs S&P 500 (26W)-49.44%
Price vs S&P 500 (4W)4.18%
Market Capitalization$15.33M
All Metrics
Book Value / Share (Quarterly)$1.73
P/TBV (Annual)0.21x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.69
Price vs S&P 500 (YTD)23.07%
Net Profit Margin (TTM)-3935.71%
EPS (TTM)$-1.55
10-Day Avg Trading Volume0.18M
EPS Excl Extra (TTM)$-1.55
EPS (Annual)$-9.05
ROI (Annual)-151.39%
Net Profit Margin (5Y Avg)-38214.76%
Cash / Share (Quarterly)$1.81
ROA (Last FY)-124.61%
EBITD / Share (TTM)$-1.52
ROE (5Y Avg)-105.54%
Operating Margin (TTM)-3957.14%
Cash Flow / Share (Annual)$-0.69
P/B Ratio0.76x
P/B Ratio (Quarterly)0.56x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)-40.69x
Net Interest Coverage (TTM)-1328.00x
ROA (TTM)-60.26%
EPS Incl Extra (Annual)$-9.05
Current Ratio (Annual)16.03x
Quick Ratio (Quarterly)15.69x
3-Month Avg Trading Volume2.70M
52-Week Price Return-40.00%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.13
P/S Ratio (Annual)766.74x
Asset Turnover (Annual)0.00x
52-Week High$4.19
Operating Margin (5Y Avg)-39948.09%
EPS Excl Extra (Annual)$-9.05
CapEx CAGR (5Y)-9.71%
Tangible BV CAGR (5Y)42.68%
26-Week Price Return-45.45%
Quick Ratio (Annual)15.69x
13-Week Price Return10.92%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)16.03x
Enterprise Value$-5.696
Asset Turnover (TTM)0.02x
Book Value / Share Growth (5Y)-42.30%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-44550.00%
Cash / Share (Annual)$1.81
3-Month Return Std Dev121.61%
Net Income / Employee (TTM)$-1
ROE (Last FY)-151.39%
EPS Basic Excl Extra (Annual)$-9.05
Receivables Turnover (TTM)0.33x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.55
ROI (TTM)-66.59%
P/S Ratio (TTM)109.53x
Pretax Margin (5Y Avg)-39834.76%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$9.52
Price vs S&P 500 (52W)-69.83%
Year-to-Date Return25.71%
5-Day Price Return5.60%
EPS Normalized (Annual)$-9.05
ROA (5Y Avg)-88.07%
Net Profit Margin (Annual)-44550.00%
Month-to-Date Return8.20%
Cash Flow / Share (TTM)$-7.19
EBITD / Share (Annual)$-9.05
Operating Margin (Annual)-44950.00%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-105.31%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.55
P/TBV (Quarterly)0.32x
P/B Ratio (Annual)0.56x
Pretax Margin (TTM)-3935.71%
Book Value / Share (Annual)$1.73
Price vs S&P 500 (13W)10.24%
Beta0.89x
Revenue / Share (TTM)$0.00
ROE (TTM)-66.59%
52-Week Low$0.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PHIOPhio Pharmaceuticals Corp. Common Stock | 109.53x | — | — | — | $1.27 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer immunotherapies using its proprietary INTASYL RNA gene silencing technology to enhance immune cells' ability to kill tumor cells. The platform precisely targets proteins that suppress anti-cancer immunity without requiring specialized drug delivery systems. The company's pipeline includes candidates PH-762 and PH-894, with all operations based in the United States.